Accredited InvestorsEmployee ShareholdersInstitutionsPrivate Companies Who We Serve Trading and Investing Data Solutions Private Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2024​Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
Solutions
Insights
About
Who We Serve
Solutions
Trading and Investing
Institutional Trading
Individual Investing
Data Solutions
Private Asset Custody
Self-Directed IRA
Insights
Private Market Reports
Market Insights
Buying and Selling Pre-IPO​
About
Log In
Sign Up
Secondary Marketplace / Trade Private Companies / Buy and Sell Intarcia Therapeutics Stock

Intarcia Therapeutics Stock

intarcia.comHealthcare / BioTech & PharmaFounded: 1995Funding to Date: $961.46MM

Intarcia is a biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease.

Learn more about Intarcia Therapeutics IPO

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Intarcia Therapeutics.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Intarcia Therapeutics stock FAQs

plusminus

Can you buy Intarcia Therapeutics stock?

You can no longer buy Intarcia Therapeutics stock on a secondary marketplace as this company ceased its operations. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Intarcia Therapeutics stock?

You can no longer sell stock of Intarcia Therapeutics on Forge as this company ceased its operations. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

What is Intarcia Therapeutics’ stock price?

Intarcia Therapeutics ceased its operations so there is no stock price available.
plusminus

What is Intarcia Therapeutics’ stock ticker symbol?

Intarcia Therapeutics ceased its operations so there is no stock ticker symbol.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Intarcia Therapeutics investors also invested in these private companies

New Enterprise Associates
GGV Capital
Venrock
Foresite Capital
Farallon Capital Management
Fred Alger Management
New Leaf Venture Partners
Quilvest
RA Capital

Explore private companies in the BioTech & Pharma sector

Colossal Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B
Altos Labs
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B
ADARx Pharmaceuticals
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM
Cytonics
Sector
Healthcare / BioTech & Pharma
 
 
AI Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM
Egenesis
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$333.77MM
Apnimed
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$366.58MM
Pendulum Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM
Element Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.05B

Team

Management Team

Paul Feldman, Ph.D.
Head of Discovery and Translational Medicine
David Spellman
Chief Business Officer and Chief Financial Officer
Thomas Alessi, Ph.D.
Vice President, Development and Manufacturing
Fred Fiedorek, M.D.
Chief Medical Officer and Global Head of Regulatory Affairs
Raymond Keane
Chief Legal Officer
Thane Wettig
Chief Commercial Officer
Jay Smith
Chief Experience Officer
Kurt Graves
Chairman, President & Chief Executive Officer
Anders Vinther, Ph.D
Global Head of Technical Operations
James Brady
Vice President, Human Resources
Andrew Young, M.B., Ch.B. (M.D.), Ph.D.
Chief Scientific Officer

Board Members

Bryan Roberts, Ph.D.
Venrock
Patrick Conway, MD
Kurt Graves
Nancy Thornberry
Bob Kerrey
Gino Santini
Jay S. Skyler, MD, MACP
Jim Rosenthal
Tokens Journal 11/11/2018

Diabetic Therapeutic Market Size, Application,Revenue, Types, Trends in Future, Scope to 2021 - TokensJournal

The Diabetic Therapeutic Market  report  provides valuable and unique information which is very  essential. Further it also covers key players,application and future market condition.This information is extremely useful information for new and growing  company to mark themself over the market Diabetic Therapeutic market to grow at a CAGR OF 7.55% during the period 2017-2021. This …
Business Insider 10/28/2018

The 25 most valuable private tech companies in the US

Tech companies are continuing to garner major venture capital investment in 2018. Here are the 25 most valuable VC-backed startups in the US.
Bitnews Today 10/28/2018

Global Diabetic Therapeutic Market 2021 Evolution Production Analysis by Price, Revenue, Cost and Gross Margin - BitsEther

Diabetic Therapeutic Market report evaluate the current opportunity and the future potential of the Diabetic Therapeutic market over the coming decade. Based on various parameters, Diabetic Therapeutic Market provides complete analysis of manufacturers, suppliers, distributors, traders, customers, major types and applications. “The global diabetic therapeutic market is growing at a high pace owing to the …
Crunchbase 06/08/2018

Comprehensive Overview of Global Non-insulin Diabetes Therapeutics Market: Growth Rate, Trends, Historical Data (2018-2025) - Cryptoinist

Questale has recently shared a new market research report on Global Non-insulin Diabetes Therapeutics market named as Comprehensive Overview of Global Non-insulin Diabetes Therapeutics Market: Growth Rate, Trends, Historical Data (2018-2025) that includes every detail related to the market. This research report includes all the historical data, market shares, sales and revenue strategies, profitability, development …
Browse More Insights
Trending Companies

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.